KalVista Pharmaceuticals/$KALV

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About KalVista Pharmaceuticals

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

Ticker

$KALV
Sector
Health
Primary listing
NASDAQ

Employees

270
Headquarters
Cambridge, United States
Website
www.kalvista.com

KALV Metrics

BasicAdvanced
$546M
-
-$3.95
-0.10
-

What the Analysts think about KALV

Analyst ratings (Buy, Hold, Sell) for KalVista Pharmaceuticals stock.

Bulls say / Bears say

The U.S. FDA’s approval of Ekterly as the first on-demand oral treatment for hereditary angioedema drove KalVista shares up over 18%, reflecting strong market confidence (Reuters)
Ekterly offers a more convenient, credit-card-sized oral alternative to bulky injectable therapies, which is likely to enhance patient adherence and market differentiation (Reuters)
Analysts at TD Cowen estimate peak U.S. sales for Ekterly could exceed $750 million, with the broader on-demand HAE segment projected to grow to $1.2 billion by 2030, indicating substantial revenue upside (Reuters)
The FDA extended its review of sebetralstat due to heavy workload and limited resources, underscoring regulatory unpredictability that could delay commercialization timelines (Reuters)
At a wholesale acquisition cost of approximately $16,720 per dose—well above existing therapies—Ekterly’s steep pricing could strain payer budgets and restrict patient access (Reuters)
With only about 8,000 hereditary angioedema patients in the U.S., the limited addressable market caps domestic revenue potential despite premium pricing (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 2 Nov 2025.

KALV Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

KALV Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

KALV News

AllArticlesVideos
KalVista Pharmaceuticals to Host Third Quarter Financial Results Conference Call and Webcast on November 11, 2025

KalVista Pharmaceuticals to Host Third Quarter Financial Results Conference Call and Webcast on November 11, 2025

Business Wire2 days ago
KalVista Pharmaceuticals Appoints Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer

KalVista Pharmaceuticals Appoints Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer

Business Wire4 weeks ago
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $KALV

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs